NO20090158L - Composition comprising naproxen nanoparticles and controlled release hydrocarbon - Google Patents
Composition comprising naproxen nanoparticles and controlled release hydrocarbonInfo
- Publication number
- NO20090158L NO20090158L NO20090158A NO20090158A NO20090158L NO 20090158 L NO20090158 L NO 20090158L NO 20090158 A NO20090158 A NO 20090158A NO 20090158 A NO20090158 A NO 20090158A NO 20090158 L NO20090158 L NO 20090158L
- Authority
- NO
- Norway
- Prior art keywords
- composition
- hydrocodone
- combination
- controlled release
- bimodal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 title abstract 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 title abstract 2
- 229960002009 naproxen Drugs 0.000 title abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
- 229930195733 hydrocarbon Natural products 0.000 title 1
- 150000002430 hydrocarbons Chemical class 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 abstract 4
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 abstract 4
- 229960000240 hydrocodone Drugs 0.000 abstract 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 4
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 abstract 4
- 230000002902 bimodal effect Effects 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Den foreliggende oppfinnelsen gjelder sammensetninger som omfatter en nanopartikulær naproksensammensetning i kombinasjon med en multipartikulær hydrokodonsammensetning for modifisert frigivelse som etter administrering til en pasient tilfører et hydrokodon på en bimodal eller multimodal måte. Den multipartikulære sammensetningen for modifisert frigivelse omfatter en første bestanddel og minst én påfølgende bestanddel hvor den første bestanddelen omfatter en første populasjon av hydrokodonholdige partikler og den minst ene påfølgende bestanddelen omfatter en andre populasjon av hydrokodonholdige partikler, hvori kombinasjonen av bestanddelene gir en bimodal eller multimodal frigivelsesprofil. Oppfinnelsen gjelder også en fast oral doseringsform som omfatter en slik kombinasjonssammensetning.The present invention relates to compositions comprising a nanoparticulate naproxen composition in combination with a modified release multiparticulate hydrocodone composition which, after administration to a patient, supplies a hydrocodone in a bimodal or multimodal manner. The modified release multiparticulate composition comprises a first component and at least one subsequent component wherein the first component comprises a first population of hydrocodone-containing particles and the at least one subsequent component comprises a second population of hydrocodone-containing particles, wherein the combination of the components provides a bimodal or multimodal release profile. . The invention also relates to a solid oral dosage form comprising such a combination composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81588506P | 2006-06-23 | 2006-06-23 | |
PCT/US2007/072052 WO2007150074A2 (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090158L true NO20090158L (en) | 2009-03-20 |
Family
ID=38834446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090158A NO20090158L (en) | 2006-06-23 | 2009-01-12 | Composition comprising naproxen nanoparticles and controlled release hydrocarbon |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2032137A2 (en) |
JP (1) | JP2009541359A (en) |
KR (1) | KR20090024284A (en) |
CN (1) | CN101484170A (en) |
AU (1) | AU2007260821B2 (en) |
BR (1) | BRPI0713447A2 (en) |
CA (1) | CA2660649A1 (en) |
IL (1) | IL196065A0 (en) |
MX (1) | MX2008016223A (en) |
NO (1) | NO20090158L (en) |
WO (1) | WO2007150074A2 (en) |
ZA (1) | ZA200810221B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
DK2826467T3 (en) | 2010-12-22 | 2017-10-16 | Purdue Pharma Lp | INCLUDED, MANIPULATION-PROPOSED SLOW-DELIVERY DOSAGE FORMS |
CN107412173A (en) | 2010-12-23 | 2017-12-01 | 普渡制药公司 | Anti-distort solid oral dosage form |
KR101794032B1 (en) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | Method for preparing nanoparticles |
KR20150059167A (en) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | Abuse deterrent pharmaceutical compositions for controlled release |
AU2014215478B2 (en) | 2013-02-05 | 2018-09-13 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US20180344649A1 (en) | 2015-09-29 | 2018-12-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
CN112500694B (en) * | 2020-12-04 | 2022-03-29 | 东莞威赢高尔夫用品有限公司 | Electronic equipment veneer material and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
WO2000025752A1 (en) * | 1998-11-02 | 2000-05-11 | Church, Marla, J. | Multiparticulate modified release composition |
ES2355723T3 (en) * | 2002-09-11 | 2011-03-30 | Elan Pharma International Limited | COMPOSITIONS OF ACTIVE AGENT IN GAN STABILIZED NANOPARTICLES. |
-
2007
- 2007-06-25 AU AU2007260821A patent/AU2007260821B2/en not_active Expired - Fee Related
- 2007-06-25 MX MX2008016223A patent/MX2008016223A/en not_active Application Discontinuation
- 2007-06-25 JP JP2009516756A patent/JP2009541359A/en active Pending
- 2007-06-25 WO PCT/US2007/072052 patent/WO2007150074A2/en active Application Filing
- 2007-06-25 KR KR1020097001439A patent/KR20090024284A/en not_active Application Discontinuation
- 2007-06-25 BR BRPI0713447-9A patent/BRPI0713447A2/en not_active IP Right Cessation
- 2007-06-25 EP EP07799011A patent/EP2032137A2/en not_active Withdrawn
- 2007-06-25 CA CA002660649A patent/CA2660649A1/en not_active Abandoned
- 2007-06-25 CN CNA2007800236169A patent/CN101484170A/en active Pending
-
2008
- 2008-12-02 ZA ZA200810221A patent/ZA200810221B/en unknown
- 2008-12-18 IL IL196065A patent/IL196065A0/en unknown
-
2009
- 2009-01-12 NO NO20090158A patent/NO20090158L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2008016223A (en) | 2009-01-19 |
AU2007260821A1 (en) | 2007-12-27 |
KR20090024284A (en) | 2009-03-06 |
AU2007260821B2 (en) | 2012-06-21 |
CN101484170A (en) | 2009-07-15 |
EP2032137A2 (en) | 2009-03-11 |
IL196065A0 (en) | 2009-09-01 |
CA2660649A1 (en) | 2007-12-27 |
WO2007150074A2 (en) | 2007-12-27 |
WO2007150074A3 (en) | 2008-04-10 |
ZA200810221B (en) | 2009-11-25 |
BRPI0713447A2 (en) | 2012-03-13 |
JP2009541359A (en) | 2009-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090158L (en) | Composition comprising naproxen nanoparticles and controlled release hydrocarbon | |
NO20090119L (en) | Composition comprising controlled release nanoparticulated meloxicam and hydrocodone | |
CY1125077T1 (en) | TREATMENT OF VITAMIN D DEFICIENCY AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3 | |
BR112012030552A2 (en) | immunogenic composition | |
CL2009000171A1 (en) | Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression. | |
CL2007003604A1 (en) | Pharmaceutical composition for oral administration comprising the amorphous 17-aminogeldanamycin compound; and its use in the treatment of cancer. | |
BR112017026586A2 (en) | microbiota restoration therapy (mrt) compositions and manufacturing methods | |
WO2010039977A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
CL2007003299A1 (en) | COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE HEPATITIS C VIRUS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C. | |
CL2011001131A1 (en) | Use of a formulation that serves to prepare a drug for an injection, which minimizes inflammation at the site of injection of an antibody, and where the formulation comprises a 2h7 antibody and variants of the antibody and polyvinylpyrrolidone (pvp) | |
UA96308C2 (en) | Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof | |
CL2007002641A1 (en) | COMPOUNDS DERIVED FROM PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF ALLERGIC DISORDERS, AUTOIMMUNES, INFLAMMATORY DISEASES. | |
GB2460597A (en) | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | |
CL2007002658A1 (en) | COMPOUNDS DERIVED FROM PURINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF AN INFLAMMATORY OR OBSTRUCTIVE DISEASE OF THE RESPIRATORY ROADS. | |
NO20064054L (en) | Therapeutic combinations of atypical antipsychotics with corticotropin release factor antagonists | |
WO2009140642A3 (en) | Tricyclic antagonists of prostaglandin d2 receptors | |
DK1748756T3 (en) | Compositions comprising molecularly dispersed drospirenone | |
SG171649A1 (en) | Dpp iv inhibitor formulations | |
WO2009102893A3 (en) | Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors | |
WO2007095091A3 (en) | Oral delivery of therapeutic agents using tight junction agonists | |
WO2006058059A3 (en) | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject | |
CL2011000976A1 (en) | Compounds derived from isonicotinamide and carboxamide, orexin receptor antagonists; pharmaceutical composition that includes them; and its use for the prevention of a sleep disorder. | |
NO20070785L (en) | Compositions for the delivery of heavily water-soluble drugs. | |
CL2012002424A1 (en) | Method for treating rheumatoid artitris which comprises administering to the patient laquinimod and methotrexate orally; pharmaceutical composition that comprises them. | |
WO2010116282A8 (en) | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |